How Much Do OECD Countries Spend on Healthcare?
When you start feeling ill, the first line of defense is typically to have a doctor assess the symptoms—but how much you end up paying for a visit differs greatly by region.
Today’s interactive visualization was created by HealthDataViz consultant Lindsay Betzendahl, who also founded #ProjectHealthViz. The data considers how healthcare spending by country stacks up across the 36 Organization for Economic Cooperation (OECD) members, and how it has changed since 2010.
One thing is clear—the United States comes in first place in each category, but that’s not necessarily a good thing:
|🇺🇸 United States||🌐 OECD Average|
|Healthcare Spending (% of GDP)||16.9% (#1)||8.8%|
|Admin Costs as % of Health Spend||8.3% (#1)*||~3%|
|Per Capita Prices (Current PPPs, USD)||$10,586 (#1)||$3,992|
*Although Costa Rica’s figure was higher in 2016, more recent data is not yet available.
Let’s look at each individual cost category, to see what else we can learn.
What Portion of GDP Goes Towards Health?
Population health is a strong determinant in quality of life. As such, how much a country spends on healthcare as a percentage of gross domestic product (GDP) can be an important indicator.
The U.S. spends 16.9% of GDP on its healthcare, nearly double the OECD average of 8.8%. That’s also over 4 percentage points (p.p.) above Switzerland, which ranks second with 12.2% healthcare spending by GDP.
The problem? While Switzerland consistently ranks as having one of the best healthcare systems in the world, the U.S. lags behind—which means that expenditures are not always translating into better health outcomes for patients.
Where’s the Money Going?
Looking after the health of millions of people is a lot of work, and this is where spending on healthcare administration and financing comes into play. Funds are allocated to medical resource providers, who manage everything from health records to salaries and insurance bills.
The U.S. spends about 8.3% of its total healthcare expenditures on these complex costs today, which is a marginal increase from 7.5% in 2010. Interestingly, Costa Rica’s healthcare spending on the same metric was even higher in 2016, at 9.5% of the total.
On the bright side, Mexico has been making strides in the past few years: administrative spending plunged from 10.3% in 2013, down to 4.6% in 2017.
Globally, advancements in health-tech are helping to reduce costs by streamlining tedious processes. However, it’s still not enough—and these immense costs trickle down to patients.
How Much Does Each Person Shell Out?
Over the past eight years, a majority of OECD countries have seen their healthcare spending per capita climb, with Luxembourg and Greece being the only exceptions. The average OECD country’s spend was $3,992 per capita in 2018, up from $3,080 in 2010—nearly a 30% increase.
However, the U.S. experiences the most dramatic sticker shock by far. At $10,586 per head, the U.S. average is already more than double the OECD average. What’s more, this is a 33.3% increase from $7,939 in healthcare spending per capita in 2010.
As the U.S. healthcare reform debate around prices and quality of care rages on, it’s important to remember that healthy people are the backbone of any country’s long-term economic growth.
Explainer: What to Know About Monkeypox
What is monkeypox, and what risk does it pose to the public? This infographic breaks down the symptoms, transmission, and more.
Explainer: What to Know About Monkeypox
The COVID-19 pandemic is still fresh in the minds of the people around the world, so it comes as no surprise that recent outbreaks of another virus are grabbing headlines.
Monkeypox outbreaks have now been reported in multiple countries, and it has scientists paying close attention. For everyone else, numerous questions come to the surface:
- How serious is this virus?
- How contagious is it?
- Could monkeypox develop into a new pandemic?
Below, we answer these questions and more.
What is Monkeypox?
Monkeypox is a virus in the Orthopoxvirus genus which also includes the variola virus (which causes smallpox) and the cowpox virus. The primary symptoms include fever, swollen lymph nodes, and a distinctive bumpy rash.
There are two major strains of the virus that pose very different risks:
- Congo Basin strain: 1 in 10 people infected with this strain have died
- West African strain: Approximately 1 in 100 people infected with this strain died
At the moment, health authorities in the UK have indicated they’re seeing the milder strain in patients there.
Where did Monkeypox Originate From?
The virus was originally discovered in the Democratic Republic of Congo in monkeys kept for research purposes (hence the name). Eventually, the virus made the jump to humans more than a decade after its discovery in 1958.
It is widely assumed that vaccination against another similar virus, smallpox, helped keep monkeypox outbreaks from occurring in human populations. Ironically, the successful eradication of smallpox, and eventual winding down of that vaccine program, has opened the door to a new viral threat. There is now a growing population of people who no longer have immunity against the virus.
Now that travel restrictions are lifting in many parts of the world, viruses are now able to hop between nations again. As of the publishing of this article, a handful of cases have now been reported in the U.S., Canada, the UK, and a number of European countries.
On the upside, contact tracing has helped authorities piece together the transmission of the virus. While cases are rare in Europe and North America, it is considered endemic in parts of West Africa. For example, the World Health Organization reports that Nigeria has experienced over 550 reported monkeypox cases from 2017 to today. The current UK outbreak originated from an individual who returned from a trip to Nigeria.
Could Monkeypox become a new pandemic?
Monkeypox, which primarily spreads through animal-to-human interaction, is not known to spread easily between humans. Most individuals infected with monkeypox pass the virus to between zero and one person, so outbreaks typically fizzle out. For this reason, the fact that outbreaks are occurring in several countries simultaneously is concerning for health authorities and organizations that monitor viral transmission. Experts are entertaining the possibility that the virus’ rate of transmission has increased.
Images of people covered in monkeypox lesions are shocking, and people are understandably concerned by this virus, but the good news is that members of the general public have little to fear at this stage.
I think the risk to the general public at this point, from the information we have, is very, very low.
–Tom Inglesby, Director, Johns Hopkins Center for Health Security
» For up-to-date information on monkeypox cases, check out Global.Health’s tracking spreadsheet
Visualizing How COVID-19 Antiviral Pills and Vaccines Work at the Cellular Level
Despite tackling the same disease, vaccines and antiviral pills work differently to combat COVID-19. We visualize how they work in the body.
Current Strategies to Tackle COVID-19
Since the pandemic started in 2020, a number of therapies have been developed to combat COVID-19.
The leading options for preventing infection include social distancing, mask-wearing, and vaccination. They are still recommended during the upsurge of the coronavirus’s latest mutation, the Omicron variant.
But in December 2021, The United States Food and Drug Administration (USDA) granted Emergency Use Authorization to two experimental pills for the treatment of new COVID-19 cases.
These medications, one made by Pfizer and the other by Merck & Co., hope to contribute to the fight against the coronavirus and its variants. Alongside vaccinations, they may help to curb extreme cases of COVID-19 by reducing the need for hospitalization.
Despite tackling the same disease, vaccines and pills work differently:
|Taken by injection||Taken by mouth|
|Used for prevention||Used for treatment only|
|Create an enhanced immune system by stimulating antibody production||Disrupt the assembly of new viral particles|
How a Vaccine Helps Prevent COVID-19
The main purpose of a vaccine is to prewarn the body of a potential COVID-19 infection by creating antibodies that target and destroy the coronavirus.
In order to do this, the immune system needs an antigen.
It’s difficult to do this risk-free since all antigens exist directly on a virus. Luckily, vaccines safely expose antigens to our immune systems without the dangerous parts of the virus.
In the case of COVID-19, the coronavirus’s antigen is the spike protein that covers its outer surface. Vaccines inject antigen-building instructions* and use our own cellular machinery to build the coronavirus antigen from scratch.
When exposed to the spike protein, the immune system begins to assemble antigen-specific antibodies. These antibodies wait for the opportunity to attack the real spike protein when a coronavirus enters the body. Since antibodies decrease over time, booster immunizations help to maintain a strong line of defense.
*While different vaccine technologies exist, they all do a similar thing: introduce an antigen and build a stronger immune system.
How COVID Antiviral Pills Work
Antiviral pills, unlike vaccines, are not a preventative strategy. Instead, they treat an infected individual experiencing symptoms from the virus.
These medications disrupt specific processes in the viral assembly line to choke the virus’s ability to replicate.
The Mechanism of Molnupiravir
RNA-dependent RNA Polymerase (RdRp) is a cellular component that works similar to a photocopying machine for the virus’s genetic instructions. An infected host cell is forced to produce RdRp, which starts generating more copies of the virus’s RNA.
Molnupiravir, developed by Merck & Co., is a polymerase inhibitor. It inserts itself into the viral instructions that RdRp is copying, jumbling the contents. The RdRp then produces junk.
The Mechanism of Nirmatrelvir + Ritonavir
A replicating virus makes proteins necessary for its survival in a large, clumped mass called a polyprotein. A cellular component called a protease cuts a virus’s polyprotein into smaller, workable pieces.
Pfizer’s antiviral medication is a protease inhibitor made of two pills:
- The first pill, nirmatrelvir, stops protease from cutting viral products into smaller pieces.
- The second pill, ritonavir, protects nirmatrelvir from destruction by the body and allows it to keep working.
With a faulty polymerase or a large, unusable polyprotein, antiviral medications make it difficult for the coronavirus to replicate. If treated early enough, they can lessen the virus’s impact on the body.
The Future of COVID Antiviral Pills and Medications
Antiviral medications seem to have a bright future ahead of them.
COVID-19 antivirals are based on early research done on coronaviruses from the 2002-04 SARS-CoV and the 2012 MERS-CoV outbreaks. Current breakthroughs in this technology may pave the way for better pharmaceuticals in the future.
One half of Pfizer’s medication, ritonavir, currently treats many other viruses including HIV/AIDS.
Gilead Science is currently developing oral derivatives of remdesivir, another polymerase inhibitor currently only offered to inpatients in the United States.
More coronavirus antivirals are currently in the pipeline, offering a glimpse of control on the looming presence of COVID-19.
Author’s Note: The medical information in this article is an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. Please talk to your doctor before undergoing any treatment for COVID-19. If you become sick and believe you may have symptoms of COVID-19, please follow the CDC guidelines.
Misc2 weeks ago
The Top 10 Largest Nuclear Explosions, Visualized
Energy3 weeks ago
Mapped: Solar and Wind Power by Country
Politics2 weeks ago
Mapped: The State of Global Democracy in 2022
Energy2 weeks ago
Visualizing U.S. Crude Oil and Petroleum Product Imports in 2021
Markets3 days ago
Made in America: Goods Exports by State
Technology3 weeks ago
Synthetic Biology: The $3.6 Trillion Science Changing Life as We Know It
Markets4 weeks ago
Why Investors Tuned Out Netflix
Markets1 week ago
Visualizing China’s $18 Trillion Economy in One Chart